HK Stock Market Move | MICOT PHARMA-B (02335) rises over 28% again, having obtained ethics approval from the lead site for the Phase III clinical trial of MT200605

MICOT PHARMA-B (02335) rose again by over 28%, up 18.8% as of press time to HK$19.32, with turnover of HK$146 million. On the news front, on the evening of November 4, MICOT PHARMA-B announced that the company, together with Beijing Tiantan Hospital, Capital Medical University (Beijing Tiantan Hospital), is jointly undertaking a research project under the National Science and Technology Major Project "Major New Drug Creation" involving the company's key product MT200605, and has recently received the first tranche of central government special funding for the project. According to the project task statement and the cooperation agreement between the two parties, the Group is responsible for the R&D, production, and clinical trial supply of MT200605. After completion of the Phase II clinical trial of MT200605, the company has received the first tranche of central government special funding for the project and is advancing the clinical development of MT200605 toward Phase III. The company has recently obtained approval from the ethics committee of the lead site (Beijing Tiantan Hospital) for the Phase III clinical trial (Phase III clinical trial) of MT200605 for the treatment of patients with acute ischemic stroke.